Form 8-K - Current report:
SEC Accession No. 0001477932-22-003195
Filing Date
2022-05-11
Accepted
2022-05-11 16:18:29
Documents
15
Period of Report
2022-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vnrx_8k.htm   iXBRL 8-K 27188
2 PRESS RELEASE vnrx_ex991.htm EX-99.1 35026
  Complete submission text file 0001477932-22-003195.txt   197997

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnrx-20220511.xsd EX-101.SCH 5830
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnrx-20220511_lab.xml EX-101.LAB 15320
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnrx-20220511_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnrx-20220511_pre.xml EX-101.PRE 9743
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnrx-20220511_def.xml EX-101.DEF 2103
9 EXTRACTED XBRL INSTANCE DOCUMENT vnrx_8k_htm.xml XML 3726
Mailing Address 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738
Business Address 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36833 | Film No.: 22913971
SIC: 2835 In Vitro & In Vivo Diagnostic Substances